Skip to main content

Health condition

Peripheral nerve tumours, from watchful waiting to specialist surgery.

Most lumps arising from a nerve are benign - schwannoma or neurofibroma. A small number are malignant and need specialist sarcoma-centre care. This guide uses UK spelling; see our US-spelling companion at peripheral nerve tumors for the same condition.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Editorial team

    Written by our editorial team from the UK sources listed on each page.

  • 02

    Sourced from guidance

    Checked against NICE, NHS England sarcoma pathway standards and peer-reviewed sources listed at the end.

  • 03

    Current for 2026

    Reflects modern UK guidance on nerve-sheath tumour imaging, biopsy and specialist centre referral.

Key facts

Peripheral nerve tumours at a glance.

The essentials, in plain English - what these tumours are, the main types, and how they are managed in the UK today.

  • What it is

    A growth arising from the cells that make up a peripheral nerve or its sheath - most are benign, a small proportion are malignant.

  • Main types

    Schwannoma and neurofibroma are the two common benign types; malignant peripheral nerve sheath tumour (MPNST) is rare.

  • NF1 link

    Neurofibromatosis type 1 raises the lifetime risk of neurofibromas and, less commonly, malignant transformation to MPNST.

  • Diagnosis

    MRI first, with targeted biopsy at a specialist sarcoma or nerve tumour centre when malignancy cannot be excluded.

  • Benign management

    Many small, stable, asymptomatic lesions are simply observed with periodic scanning rather than operated on.

  • Malignant management

    Wide surgical excision, usually with radiotherapy, delivered through a specialist sarcoma multidisciplinary team.

Why this guide matters

Most are benign - but the exceptions matter.

A lump on a nerve is often nothing sinister. The three points below explain why careful imaging and, sometimes, specialist referral still matter.

  • Benign disease is common

    Schwannoma and neurofibroma are the two everyday diagnoses - many need nothing more than monitoring.

  • NF1 changes the picture

    People with neurofibromatosis type 1 need a tailored surveillance plan because of the small malignant-transformation risk.

  • MPNST needs urgent specialist care

    Malignant peripheral nerve sheath tumour is rare but aggressive - early referral to a sarcoma centre improves outcomes.

How the diagnosis is made

From first lump to a clear plan.

The steps a UK GP, neurologist or sarcoma team will normally follow, in order - so you know what to expect and why.

  1. 01

    Assessing

    History and examination

    A GP or specialist checks for a slow-growing lump, tingling, pain on tapping (Tinel sign), and any family or personal history of NF1.

  2. 02

    Assessing

    MRI of the affected area

    The first-line imaging test - it defines the nerve of origin, size, and features suggestive of benign versus malignant disease.

  3. 03

    Assessing

    Growth-rate assessment

    Rapid enlargement, new pain, or new weakness are the features that most raise concern for malignant change.

  4. 04

    Confirming

    Referral to a specialist centre

    Any lesion with concerning MRI features, or any suspected MPNST, is referred to a regional sarcoma or peripheral nerve tumour service.

  5. 05

    Confirming

    Image-guided or open biopsy

    Performed at the specialist centre - never before referral - to avoid seeding tumour cells along the wrong track.

  6. 06

    Preparing

    Multidisciplinary team review

    Imaging, histology and clinical findings are reviewed together by sarcoma surgeons, oncologists, radiologists and pathologists.

  7. 07

    Preparing

    Genetic and NF1 assessment

    Where NF1 is suspected, referral to clinical genetics helps guide long-term surveillance and family counselling.

Typical timeline: MRI within weeks, specialist opinion soon after if imaging is not clearly benign.

Symptoms

What a nerve tumour actually feels like.

Often a painless, slow-growing lump - and, in some, features that mean it's time to move quickly.

  • Slow-growing lump

    A soft, mobile swelling along the course of a nerve, often present for months or years before it is noticed.

  • Tingling or pins and needles

    Pressure on the nerve fibres can cause paraesthesia in the area the nerve supplies.

  • Tinel sign

    Tapping over the lump reproduces tingling down the nerve - a classic clinical clue to a nerve-sheath origin.

  • Multiple neurofibromas

    Numerous small, soft skin nodules are typical of neurofibromatosis type 1 rather than a solitary schwannoma.

  • Café-au-lait patches

    Flat, light-brown skin patches are an associated NF1 feature worth mentioning to your clinician.

  • Deep, dull ache

    Larger or deeper lesions, particularly in the limbs or pelvis, can cause a persistent dull ache.

  • New weakness

    Progressive weakness in the muscles supplied by the affected nerve needs prompt specialist assessment.

  • Red flag - rapid growth or new pain

    Fast enlargement, new severe pain, or new neurological deficit are the key signals of possible malignant change.

Treatment

How peripheral nerve tumours are treated in the UK.

Observation for stable benign disease, careful nerve-sparing surgery when needed, and wide excision plus radiotherapy for confirmed malignant disease.

  • Active surveillance

    Small, stable, asymptomatic benign lesions are often simply monitored with periodic clinical review and imaging.

  • Marginal excision (schwannoma)

    Schwannomas usually shell out cleanly from the nerve, often preserving nerve function - the standard approach for symptomatic benign lesions.

  • Careful excision (neurofibroma)

    Neurofibromas are more intimately woven into the nerve fibres, so surgery is planned to balance symptom relief against the risk of nerve damage.

  • Wide surgical excision (MPNST)

    Malignant peripheral nerve sheath tumours need excision with a clear margin of healthy tissue, performed at a specialist sarcoma centre.

  • Adjuvant radiotherapy

    Used alongside surgery for MPNST, particularly with larger tumours or close margins, to reduce the chance of local recurrence.

  • Chemotherapy

    Considered for MPNST with metastatic spread or where surgery and radiotherapy alone are unlikely to be curative.

  • Nerve reconstruction

    Nerve grafting or transfer may be planned alongside excision when a functionally important nerve segment must be sacrificed.

  • NF1 surveillance programme

    Regular specialist review for people with NF1, watching for lesions that grow quickly or change in character over time.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and specialist sarcoma-service standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your GP or specialist knows your history and imaging and can tell you which parts apply to you. If in doubt, get seen.

  • NICE. Improving outcomes for people with sarcoma (CSG9) and related referral guidance.

  • NHS England. Sarcoma services specification - specialist nerve tumour and MPNST pathways.

  • European Society for Medical Oncology (ESMO). Soft tissue and visceral sarcomas: clinical practice guideline.

  • Neurofibromatosis Association / genetics services. NF1 surveillance and management guidance.

Red flags

When a nerve lump needs urgent attention.

Most peripheral nerve tumours are manageable in routine care. These are the situations that aren't - and where a specialist opinion is needed quickly.

  • Rapid growth

    A lump that enlarges noticeably over weeks rather than months is a strong signal for urgent specialist assessment.

  • New or worsening pain

    Pain that develops or intensifies in a previously stable, painless lump raises suspicion of malignant change.

  • New neurological deficit

    New weakness, numbness or loss of function in the area the nerve supplies needs prompt referral.

  • Lesion over 5cm

    Larger soft-tissue masses carry a higher likelihood of malignancy and should follow the sarcoma referral pathway.

  • Suspected MPNST in NF1

    People with NF1 who develop a rapidly growing or newly painful plexiform neurofibroma need urgent specialist review.

  • Deep-seated or fixed lump

    A mass that feels fixed to deeper tissue, rather than mobile, is another feature that warrants urgent imaging.

  • Systemic symptoms

    Unexplained weight loss or fatigue alongside a growing lump should prompt urgent, not routine, referral.

  • Post-biopsy concerns

    A biopsy performed outside a specialist centre can complicate later surgery - always seek sarcoma centre input first.

  • Local recurrence

    Any new swelling at a previous excision site, benign or malignant, should be reassessed by the original specialist team.

Living with it

A manageable condition, with a clear follow-up plan.

Four things that make the biggest difference - keeping review appointments, tracking change, knowing your NF1 plan if relevant, and acting fast on new symptoms.

A quiet reminder

Watchful waiting is an active decision, not inaction.

Choosing to monitor a stable benign lesion is a considered clinical plan - not the same as ignoring it.

  1. 01 Monitor

    Keep review appointments

    Even stable, benign lesions are usually followed up periodically - attending these appointments catches change early.

  2. 02 Notice

    Track size and sensation

    A simple note of size, tenderness or tingling over time helps your clinician spot meaningful change quickly.

  3. 03 NF1

    Know your surveillance plan

    If you have neurofibromatosis type 1, ask your team what surveillance schedule applies to you and stick with it.

  4. 04 Escalate

    Act on new symptoms promptly

    New pain, growth or weakness should not wait for the next scheduled appointment - contact your specialist team directly.

Frequently asked

Everything we get asked about peripheral nerve tumours.

Quick answers on schwannoma, neurofibroma, NF1 and malignant peripheral nerve sheath tumour.

  • What is a peripheral nerve tumour?

    A growth arising from a peripheral nerve or the cells that form its protective sheath. Most - schwannomas and neurofibromas - are benign, while malignant peripheral nerve sheath tumours (MPNST) are rare. This UK guide uses British spelling; our companion US-spelling article covers the identical condition at /conditions/peripheral-nerve-tumors.

  • Is a peripheral nerve tumour usually cancerous?

    No. The great majority of peripheral nerve sheath tumours are benign schwannomas or neurofibromas. MPNST is uncommon and is more often seen in people with neurofibromatosis type 1.

  • What is the link with neurofibromatosis type 1?

    NF1 is a genetic condition that predisposes to multiple neurofibromas and carries a small but real lifetime risk of one transforming into a malignant peripheral nerve sheath tumour, which is why regular surveillance matters.

  • How is a peripheral nerve tumour diagnosed?

    MRI is the first-line investigation, showing the tumour and its relationship to the nerve. If malignancy cannot be excluded, biopsy is arranged at a specialist sarcoma or nerve tumour centre rather than locally.

  • Will I need surgery?

    Not always. Small, stable, symptom-free benign lesions are often simply observed. Surgery is offered for symptomatic or growing benign tumours, and is essential - alongside radiotherapy in many cases - for confirmed malignant disease.

  • What are the warning signs I should not ignore?

    Rapid growth, new or worsening pain, and new weakness or numbness are the key red flags. Any of these, especially in someone with NF1, warrants urgent specialist assessment rather than routine follow-up.

Related content

Keep reading.